Human triple-negative breast cancer cells
CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients
13
A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer
14
Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response
17
Increased macroH2A1.1 Expression Correlates with Poor Survival of Triple-Negative Breast Cancer Patients
13
miR-720 is a downstream target of an ADAM8-induced ERK signaling cascade that promotes the migratory and invasive phenotype of triple-negative breast cancer cells.
20
A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer
14
en fr Strategies of Cancer Immunotherapy : Model of Triple Negative Breast Cancer Stratégie d'immunothérapie des cancers : modèle de cancer du sein triple négatif
283
Statistical and algorithmic developments for the analysis of Triple Negative Breast Cancers
277
In Vivo Assessment of VCAM-1 Expression by SPECT/CT Imaging in Mice Models of Human Triple Negative Breast Cancer
14
Human breast cancer cells educate macrophages toward the M2 activation status
15
TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer
16
New Insights into the Implication of Epigenetic Alterations in the EMT of Triple Negative Breast Cancer
22
Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies
57
Role of stable free radicals in conjugated antioxidant and cytotoxicity treatment of triple negative breast cancer
22
CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer
28
Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis
12
EHD2 is a Predictive Biomarker of Chemotherapy Efficacy in Triple Negative Breast Carcinoma
13
View of Triple Negative Breast Cancer: A review of common therapeutic Targets and Current Treatment options.
4
Transactivation of vimentin by beta-catenin in human breast cancer cells
13
Modeling Heterogeneity of Triple‐Negative Breast Cancer Uncovers a Novel Combinatorial Treatment Overcoming Primary Drug Resistance
18